Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

WSG-ADAPT: Trastuzumab Emtansine ± ET vs Trastuzumab + ET in HER2+/HR+ Early Breast Cancer
Slideset - Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 15, 2015 Category: Cancer & Oncology Source Type: research

ClinicalThought™ Highlights Module 2
Learning Module - In these highlights from the ClinicalThought™ program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of breast cancer, chronic myeloid leukemia, glioblastoma, immune thrombocytopenia, diffuse large B-cell lymphoma, melanoma, multiple myeloma, and prostate cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - May 24, 2013 Category: Cancer & Oncology Source Type: research

ClinicalQuiz™: Metastatic Breast Cancer Edition
Learning Module - This CME-certified activity provides clinical management insights from leading experts on the care of patients with metastatic breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - May 16, 2013 Category: Cancer & Oncology Source Type: research

Progress in Treatment of Metastatic HER2+ Breast Cancer
CCO Slideset - This downloadable slideset, presented by Mohammad Jahanzeb, MD, at the NCCN 18th Annual Conference, reviews the current standard of care in the treatment of HER2-positive metastatic breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - March 20, 2013 Category: Cancer & Oncology Source Type: research

Endocrine Therapy for Metastatic Breast Cancer
CCO Slideset - This downloadable slideset, presented by Joyce O’Shaughnessy, MD, at the NCCN 18th Annual Conference, reviews the current standard of care in the treatment of hormone responsive metastatic breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - March 20, 2013 Category: Cancer & Oncology Source Type: research

Approaches to Patients Without Altered HER2 or ER/PgR: Triple-Negative Breast Cancer (TNBC)
CCO Slideset - This downloadable slideset, presented by Lee Schwartzberg, MD, FACP, at the NCCN 18th Annual Conference, reviews the current standard of care in the treatment of triple-negative metastatic breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - March 20, 2013 Category: Cancer & Oncology Source Type: research

Faculty Answers to More Questions on the Management of Bone Health
Learning Module - In this CE-certified module, Gloria (Lita) Smith, MS, RN, ACNP; Linda A. Jacobs, PhD, RN; and Kristi Orbaugh, RN, MSN, RNP, AOCN, answer your most frequently asked questions on the optimal management of bone health in patients with a history of cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - March 5, 2013 Category: Cancer & Oncology Source Type: research

Breast Cancer: CCO Independent Conference Highlights of the 2012 San Antonio Breast Cancer Symposium
CCO Slideset - In this downloadable slideset, Peter Ravdin, MD, and Joyce O’Shaughnessy, MD, review and assess key data in breast cancer management presented at the 2012 San Antonio Breast Cancer Symposium. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - January 28, 2013 Category: Cancer & Oncology Source Type: research

New Clinical Perspectives for Cancer Care: Optimizing Therapeutic Strategies Targeting Bone
Learning Module - In this educational video, Noopur Raje, MD; Alison T. Stopeck, MD; Howard (Jack) West, MD; and Evan Y. Yu, MD, discuss important concepts and emerging data on the use of bone-targeted therapy for patients with solid and hematologic tumors. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - January 15, 2013 Category: Cancer & Oncology Source Type: research

Clinical Focus: Current Approaches to the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
CCO Slideset - Denise A. Yardley, MD, explores current treatment options for hormone receptor–positive, HER2-negative metastatic breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - January 15, 2013 Category: Cancer & Oncology Source Type: research

Expert Guidance on Choice of Bone-Targeted Therapy for Patients With Breast Cancer
Resource - This Interactive Decision Support Tool will allow you to view expert treatment recommendations based on patient characteristics that you provide. The expert recommendations are based on input from Adam M. Brufsky, MD PhD; Robert E. Coleman, MD, FRCP; Allan Lipton, MD; Alison T. Stopeck, MD; and Katherine N. Weilbaecher, MD. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 19, 2012 Category: Cancer & Oncology Source Type: research

Expert Discussion on the Optimal Use of Bone-Targeted Agents in Breast Cancer
Learning Module - In this educational activity, Robert E. Coleman, MD, FRCP, and Alison T. Stopeck, MD, use case vignettes to discuss important concepts and emerging data on the use of bone-targeted therapy for patients with breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 13, 2012 Category: Cancer & Oncology Source Type: research

Addition of Trastuzumab to Paclitaxel After AC Chemotherapy Associated With Significantly Improved OS and DFS: Final Joint Analysis of NSABP B-31 and NCCTG N9831
Capsule Summary - The significant improvement in OS and DFS patients with high-risk HER2-positive early breast cancer was seen across multiple patient subsets. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

BEATRICE: No Significant Improvement in Invasive DFS with Addition of Bevacizumab to Adjuvant Chemotherapy for Triple-Negative Early Breast Cancer
Capsule Summary - The BEATRICE study showed that despite promising results with bevacizumab in triple-negative metastatic breast cancer, its addition to adjuvant chemotherapy offered no benefit for triple-negative early breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

8-Year HERA Results: 2 Years of Trastuzumab Therapy Does Not Improve Outcomes vs 1 Year Therapy Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer
Capsule Summary - These findings, in tandem with the durable benefits seen with 1 year of trastuzumab compared with observation, confirm that adjuvant trastuzumab for 1 year remains standard of care for patients with HER2-positive early breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research